Table 2.

Comparing pharmacology of novel non statin hypolipidemic drugs.

Drugs	Alirocumab (PCSK-9 inhibitor)	Evolocumab (PCSK-9 inhibitor)	Inclisiran	Bempedoic acid
Dose	75–150mg Bi-weekly or 300 mg monthly	140mg Bi-weekly or 420 mg monthly	100–150mg Every 6 months	180mg Once daily
Route	Subcutaneous	Subcutaneous	Subcutaneous	Oral
Metabolism	Binds to PCSK9 enzyme and proteolysis	Binds to PCSK9 enzyme and proteolysis	–	–
Elimination t1/2	11–20 days	11–20 days	–	15–24hrs
Effectiveness (%LDL-C reduction)	45–60% [28]	∼60% [29]	35.5–52.6% [30]	17–48% [31]